To present a new grouping of male patients with lower urinary tract symptoms (LUTS) based on symptom patterns and clarify whether the therapeutic effect of α1-blocker differs among the groups.
We performed secondary analysis of anonymous data from 4815 patients enrolled in a postmarketing surveillance study of tamsulosin in Japan.
Data on 7 International Prostate Symptom Score (IPSS) items at the initial visit were used in the cluster analysis. IPSS and quality of life (QOL) scores before and after tamsulosin treatment for 12 weeks were assessed in each cluster. Partial correlation coefficients were also obtained for IPSS and QOL scores based on changes before and after treatment.
Five symptom groups were identified by cluster analysis of IPSS. On their symptom profile, each cluster was labeled as minimal type (cluster 1), multiple severe type (cluster 2), weak stream type (cluster 3), storage type (cluster 4), and voiding type (cluster 5). Prevalence and the mean symptom score were significantly improved in almost all symptoms in all clusters by tamsulosin treatment. Nocturia and weak stream had the strongest effect on QOL in clusters 1, 2, and 4 and clusters 3 and 5, respectively.
The study clarified that 5 characteristic symptom patterns exist by cluster analysis of IPSS in male patients with LUTS. Tamsulosin improved various symptoms and QOL in each symptom group. The study reports many male patients with LUTS being satisfied with monotherapy using tamsulosin and suggests the usefulness of α1-blockers as a drug of first choice.
Urology 2015 Jul 17 [Epub ahead of print]
Ken Aikawa, Masao Kataoka, Soichiro Ogawa, Hidenori Akaihata, Yuichi Sato, Michihiro Yabe, Junya Hata, Tomoyuki Koguchi, Yoshiyuki Kojima, Chihaya Shiragasawa, Toshimitsu Kobayashi, Osamu Yamaguchi
Department of Urology, Fukushima Medical University, Fukushima, Japan Electronic address: kaika@fmu ac jp , Department of Urology, Fukushima Medical University, Fukushima, Japan , Department of Urology, Fukushima Medical University, Fukushima, Japan , Department of Urology, Fukushima Medical University, Fukushima, Japan , Department of Urology, Fukushima Medical University, Fukushima, Japan , Department of Urology, Fukushima Medical University, Fukushima, Japan , Department of Urology, Fukushima Medical University, Fukushima, Japan , Department of Urology, Fukushima Medical University, Fukushima, Japan , Department of Urology, Fukushima Medical University, Fukushima, Japan , Medical Affairs, Astellas Pharma Inc , Tokyo, Japan , Medical Affairs, Astellas Pharma Inc , Tokyo, Japan , Division of Bioengineering and LUTD Research, Nihon University College of Engineering, Koriyama, Japan